| Literature DB >> 26130164 |
Hayato Iwase1, Hong Liu1,2, Martin Wijkstrom1, Huidong Zhou1,3, Jagjit Singh1, Hidetaka Hara1, Mohamed Ezzelarab1, Cassandra Long1, Edwin Klein4, Robert Wagner4, Carol Phelps5, David Ayares5, Ron Shapiro1, Abhinav Humar1, David K C Cooper1.
Abstract
The longest survival of a non-human primate with a life-supporting kidney graft to date has been 90 days, although graft survival > 30 days has been unusual. A baboon received a kidney graft from an α-1,3-galactosyltransferase gene-knockout pig transgenic for two human complement-regulatory proteins and three human coagulation-regulatory proteins (although only one was expressed in the kidney). Immunosuppressive therapy was with ATG+anti-CD20mAb (induction) and anti-CD40mAb+rapamycin+corticosteroids (maintenance). Anti-TNF-α and anti-IL-6R were administered. The baboon survived 136 days with a generally stable serum creatinine (0.6 to 1.6 mg/dl) until termination. No features of a consumptive coagulopathy (e.g., thrombocytopenia, decreased fibrinogen) or of a protein-losing nephropathy were observed. There was no evidence of an elicited anti-pig antibody response. Death was from septic shock (Myroides spp). Histology of a biopsy on day 103 was normal, but by day 136, the kidney showed features of glomerular enlargement, thrombi, and mesangial expansion. The combination of (i) a graft from a specific genetically engineered pig, (ii) an effective immunosuppressive regimen, and (iii) anti-inflammatory agents prevented immune injury and a protein-losing nephropathy, and delayed coagulation dysfunction. This outcome encourages us that clinical renal xenotransplantation may become a reality.Entities:
Keywords: anti-IL-6R antagonist; costimulation blockade; genetically engineered; kidney; pig; xenotransplantation
Mesh:
Substances:
Year: 2015 PMID: 26130164 PMCID: PMC4519393 DOI: 10.1111/xen.12174
Source DB: PubMed Journal: Xenotransplantation ISSN: 0908-665X Impact factor: 3.907